ANKRD34A Inhibitors
ANKRD34A inhibitors are a diverse group of compounds that interfere with the protein's function through several distinct yet interconnected biochemical pathways. Trichostatin A, for example, disrupts chromatin structure, potentially suppressing key genes necessary for ANKRD34A's activation or stabilization. LY 294002 and Wortmannin, both PI3K inhibitors, compromise the AKT signaling pathway, which is critical for post-translational modifications that ANKRD34A may require. Similarly, PD 98059 and U0126, by targeting MEK1/2 within the MAPK/ERK pathway, could lead to an indirect reduction in ANKRD34A's activity by altering the cellular context in which it operates. SB 203580 specifically targets p38 MAP kinase, potentially affecting the phosphorylation of substrates vital for ANKRD34A's stability or signaling requirements.
Rapamycin, by inhibiting mTOR, disrupts essential protein synthesis and degradation pathways, which could be crucial for ANKRD34A maintenance, while NF449 directly inhibits Gαs, possibly affecting G-protein-coupled receptor signaling pathways that regulate ANKRD34A. Y-27632's inhibition of ROCK could interfere with cytoskeletal dynamics, important for ANKRD34A's function, and SP600125 disrupts JNK signaling, affecting gene expression related to ANKRD34A's role in the cell. Brefeldin A targets ARF, disrupting vesicle trafficking and potentially affecting ANKRD34A's cellular localization, while Gö 6976 inhibits PKC, which may lead to a decrease in ANKRD34A's activity through diminished cell growth and differentiation signaling. Collectively, these inhibitors utilize various mechanisms to diminish the functional activity of ANKRD34A, revealing the intricate web of cellular pathways that govern and modulate its action.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A is a histone deacetylase inhibitor that increases the acetylation of histones, leading to changes in chromatin structure and gene expression. Since histone acetylation can affect the transcription of numerous genes, the inhibition of deacetylases can result in the suppression of genes that are critical for the activation or stabilization of ANKRD34A's function. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a potent inhibitor of phosphoinositide 3-kinases (PI3K), which play a pivotal role in various cellular processes, including growth, survival, and metabolism. By inhibiting PI3K, LY294002 can disrupt downstream signaling pathways such as AKT, which may be crucial for the post-translational modification or localization of ANKRD34A, hence indirectly inhibiting its function. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD 98059 is a selective inhibitor of mitogen-activated protein kinase kinase (MEK), which is involved in the MAPK/ERK pathway. This pathway is involved in cell growth and differentiation. By inhibiting MEK, PD 98059 can indirectly affect the cellular context that ANKRD34A operates within, potentially leading to a functional decrease in ANKRD34A activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB 203580 is a specific inhibitor of p38 MAP kinase, which is involved in the response to stress stimuli and inflammatory cytokines. As p38 MAP kinase is responsible for phosphorylating various substrates, its inhibition by SB 203580 could interfere with the cellular signaling required for ANKRD34A's activity or stability. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is a specific mTOR inhibitor. The mTOR pathway is crucial for cell growth and proliferation. By inhibiting mTOR, Rapamycin may disrupt processes that are essential for the maintenance of ANKRD34A, including protein synthesis and degradation, thus diminishing its functional activity. | ||||||
NF449 | 627034-85-9 | sc-478179 sc-478179A sc-478179B | 10 mg 25 mg 100 mg | $203.00 $469.00 $1509.00 | 1 | |
NF449 is a potent and selective inhibitor of Gαs subunit of G-proteins. G-proteins are involved in numerous signaling pathways. By inhibiting Gαs, NF449 could diminish the G-protein-coupled receptor signaling that may regulate processes critical for ANKRD34A's function. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 is an inhibitor of the Rho-associated protein kinase (ROCK). ROCK plays a significant role in cytoskeletal dynamics. Since the cytoskeleton is essential for numerous cellular functions, Y-27632 could interfere with cellular architecture or motility aspects that are necessary for ANKRD34A's proper activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which is involved in controlling gene expression related to cell proliferation and apoptosis. Inhibition of JNK by SP600125 could alter the expression of genes or the signal transduction pathways that are crucial for ANKRD34A's activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent inhibitor of phosphoinositide 3-kinases (PI3K). Similar to LY294002, it disrupts the PI3K/AKT pathway. Wortmannin can decrease the phosphorylation events that may be essential for ANKRD34A's role in the cell. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Brefeldin A is an inhibitor of ADP-ribosylation factor (ARF), which is a small GTPase involved in vesicle trafficking. By inhibiting ARF, Brefeldin A disrupts the Golgi apparatus and protein trafficking, which could diminish ANKRD34A's trafficking to its site of action or its secretion if it is a secreted protein. | ||||||